We conducted a prosp eeti ve, randomized, controlled, doub le-blind study of33 patients to comp are the efficaey andtolerability ofa new g lycerinform ulation of ototopi cal 0.3% cip roflo xacin with that of a conventional aqu eous fonnulation of eiproflo xacin fo r the treattnent of acute external otitis. Out cotnes tneasures were reso lution of disch arg e, swelling, p ain . and redness and the inci denee ofadverse side eJJeets. Pat ients were exa tnined on three oec asions: on the day ofenrollme nt (visit 1) , 48 to 72hours later (visit 2), and 7 day s after enrollme nt (visit 3). At visit 2. the patients in the gly cerin group sho wed a significantly great er reso lution of discharg e. We observed the SG1ne pattern with resp eet to sw elling, pain, and redness, which resolved mare qu ickly in the g lyce rin group . although not signifiea ntly so. All patients were cured by visit 3, and the two treatments were equally weil tolerated. On the basis ofourfindings , we conelude that the glycerinfon nulation ofototop ieal 0.3 % cip rofloxac in app ears to be at least as eJJeetive as the aqueous f orm in the treatm ent of acute external otitis-i-and in the ease of otorrhe a, ma re so .
Introduction
Drugs used topically in the ear are gen erall y fonnulated into solutions or su spension s in a vehicle of anhy drous glyce rin or propyl ene glycol.' -' Th e use of these viscou s vehicles allows for max imum contact tim e bet we en the medic ati on and the tissue s of the ear. In addition, these vehic les are hygro scopic-that is, they draw moi sture from the tissues, there by diminish ing the moisture avai labl e to infectin g micro organi sms and reducing inflamma tion.' From Acute externa l otit is (AEO) is the mos t common infection ofthe extern al auditory can al. Th is painful condition is the con sequ ence of a secondary infe ct ion of macerated sk in and subcutaneous tissu es of the externa l auditory can al. Th e most common clini calmanifest ation of AEO is pain whe n the pinn a is touch ed or pull ed or when pres sure is placed on the tragu s. Other signs include drainage fro m the cana l, swelling, redn ess, and pruritus. ' Expos ure of the ear to wa ter can predi spose patien ts to this cond ition .
Manageme nt ofAE O w ith ototopical agents is commo n prac tice among otolaryngologists.' Several combinations of ototopical preparati on s are avai lable to treat extern al and middle ear infections. Th e maj or components of these products are antiinfectives suc h as po lymyxi n B, neo mycin, gentamicin, and chloramphe nico l in a nonaqu eous hy gro scopic vehicle, to whi ch a corticos tero id is freque ntly add ed . Som e of these agents are reco gnized as ototo xic, and there is convincing evide nce that they can cause senso rineural hearing loss in animals. Because Pseudo inonas aeruginosa , Staphy lococcus aureus , gram-negative baci lli, and anae robic orga nisms alone or in combination are the predominant sources ofinfecti on , it is important to rely on medic ations that have a broad spectru m of activity.'
Cipro floxa cin was the first f1uor oquinolone to becom e ava ilable as an otot opi cal preparation . No evidence ofototoxicity afte r topica l application of cipro floxa cin in 1.55-to 7.5-mg/m l so lutions has been see n in eit her animal or cl inical studies.' Ciprofloxaci n has been sho wn to be effecti ve aga inst the path ogens that are commo nly associated w ith ea r infec tio ns, including P aerug inosa and methi cillinresistant S aureus. Cip rofloxacin has not been detec ted in plasma foll owing ototopical applica tio ns, suggesting that sys temic absorption is negli gible. Thi s fact allows it to be used in children younge r than 18 yea rs, for wh om oral ci profloxac in is approved on ly for co mplicated urin ary tract infec tion and pyeloneph ritis.v-? Th erefore, top ieal antibiotic form ulations such as ciprofloxacin eardrops that have an appropriate antimicrobial spe ctrum and that confer no risk of ototoxic ity are va luable tool s for the therapeutic mana gement of ear infections.
O UVERA, SISTONI , AN UN, SAU NAS, MANZO BeCaLISe the solubility of ciprofloxaci n is low in water, glycerin, and propylene glycol," it has been fonnulated as an aqueous solution of its hydrochloride (HCI) salt. Therefore, the pH of this fonnulation is approximately 4. There are several commercially available ciprofloxacin otic fonnulationsthathave a concentration of 0.2 to 0.3%. Ciprofloxac in is alsocombined with either hydrocortisonc or dexamethasone.Currentcompositions are made up of the active drug in an aqueous vehicle, a pH-regulating agent, a thickening agent, and an antimicrobial preservative.
To overcome the drawbacks associated with ciprofloxacin's low solubility, we developed a new ototopical formulation-O.3% ciprofloxacin in a glycerin vehicle-by increasing the apparent solubility in this medium through aluminum cornplexation.? The glycerin replaces the water, which has bcen associated with trauma and epithelial damage in ear tissues, and it avoids an acidic pH, which is known to strongly reduce ciprofloxacin's antimic robial activity." Another advantage of using glycerin is that additionalantimicrobialpreservation is not necessary because this function is fulfi lled by the glycerin itself when its concentration is greater than 20%. 2 Because systemic absorption of topieal products is negligible and because ciprofloxaein does not produee an aeute pharmacologic effeet that eould be monitored, the appropriate way to assess the effieaey and tolerability of the new ciprofloxaci n glycerin produet, aecording to the literature,I I is a controlled elinieal trial.
Our objective was to compare the therapeutie effieaey and tolerabilityofthe0.3% eiprofloxaein glyeerin solution with that of the standard 0.3% eiprofloxaein aqueous solution.Thestudyhypothesis was that while both formulations would be equivalent in terms of eradicating pathogens, they might have different effeets in terms of alleviating discharge, swelling, pain, and redness.
Patients and methods
Patients. Inclusion criteria were ( I) the presenee of AOE manifested as drainage, swelling, pain, and/or erythema in the external ear canal, (2) bacteriologie eonfirmation of infection, and (3) an ability to follow investigators' instructions. Exclusion eriteria were ( I) the presenee of an allergy or contraindication to qu inolones, (2) the need to start an incompatible treatment durin g the study period, (3) the presence ofa chronie illness that required long-term pharmacologic therapy, and (4) partieipation in another c1 inical trial during the previous 15 days.
Fortnulations. Toensure the integrity oft he preparations and to enablea double-blind des ign, both the aqueous and glycerin formulations were prepared under aseptie eonditions at the Departamento de Faunaei a at the Faeultad de CienciasQuimicas ofthe Universidad Naeionalde Cordeba inArgentina.Thesolution contain ing the 0.3% ciprofloxaein in asteriIe glycerin vehiele was aseptieally prepared according to the patent application in transit.'? The 0.3% 626 eiprofloxaein aqueous solution was prepared by aseptieally assernbling its components aeeording to the stated formula on the label ofa commercially available produet (table I) . The final solution was filtered through a sterile-sterilizing 0.2-fl Millipore filter. Both formulations were paeked in IO-ml polyvinyl ehloride droppers labeled with randomly generated numbers." The droppers were given to physieians who were blinded to the vehicle in eaeh.
Study design, This prospeetive, randorn ized, controlled, cornparative, double-b lind trial was designed aeeording to guidelines established by Argentina's Administracion Naeional de Medicamentos, Alimentos y Tecnologia Medica.'" The study was eondueted between Jan. 18 and May 30, 200 3, by otolaryngo log ists at the Cliniea Privada de la Familia in Cordoba, Argentina; the study protocol was approved by that eenter 's Ethieal Review Committee. Partieipants reeeived detailed inforrnation on the study, including a patient information sheet, and written eonsent was obtained from all patients or their parents before enrollment.
Patients were randorn ly alloeated to reeeive either the aqueous or glyeerin solution at a dosage of 3 drops twice daily for 7 days." All patients were taught how to eorrectly apply their drops. They were advised to warm the dropper with their hands until the drops aehieved room temperature in order to avoid the vertigo that ean oeeur when a cold c1rop is instilled into the ear. They were instrueted to apply the medication while they were in asupine position with the target ear faeing the eeiling. They were to introduee the drops into the external meatus and to massage the tragus for 30 to 60 seeonds.
Patients were examined on three oeeasio ns: on the c1ay of enrollment (visit 1), 48 to 72 hours later (visit 2), and 7 days after the beginnin g of treatment (visit 3). The c1 inieal endpoint was a comp lete eessation of AEO symptoms.
At each visit, the physieians reeorded the degree of ear drainage, swelling, pain, and redness as weil as any side effeets of the drug (e.g., pruritus, pain, or burning): tneir ymplO,",u ing """', method>. membtuno<. H"nnon ,,,id anotbet A W_Madi,on "udy has snov n Rab"go said Ih"t the palients who "d,,,nlUg e i' that the suline 'olution thal "n inexp,n,i" o",_the-eounte' uscd nUS", illigation, .."pe",need used is good fo' keeping "I bay the ueatn"IU p""ides pe"''''''' the WI ,ignif""nl imp.o"menl eomp"ted 10 germ that e"uSO colds and Ilu telief fo. a eom mon but 'exing ailinose who did not," He . ,id they . Dra inage. Discharge from the cana l was classified as either purul ent or 1II 11CO/ IS . Any change fro m purulent to mucous was co nsidere d an improve me nt-as, of course, was complete resolut ion of otorrhea .
Swelling. Swe lling was diagnosed by oto microsco py and class ified acco rding to how far it extended through the externa l ear ca na l as either sliglit (one -third of the cana l), moderat e (two -thirds) , or intense (the entire ca nal).
Pain. Pain was reco rded as either ex iste nt or no nex isten t acco rding to the pat ient' s reac tion when the tragus was pressed.
Redness. Oto microscopy was also used to classify redness as either ex istent or no nexistent, Side effecls. Patients were aske d about any discom fort or unpleasant sensat ions they might have ex perienced when they instilled their drops.
Pathogens. At visit I, the investiga tors obtained an ear swa b for culture , inoc ulated it into appro priate agar media, and identified the pathoge ns afte r incubation by standard microbiologic techniques. Sensitivity to ciprofloxaci n was tested by the disk method.' Bacteriologic tests were also carrie d out.
Statistical analy sis. Afte r treatm ent was completed, the findings we re reviewed by the study monit or for final rev iew, data clean ing, and final statist ical analysis. Th e chi-square d test was used to calc ulate and compare the percentages of responses in both gro ups .
Results
A total of 37 pat ients were initially enro lled in the study and alloca ted to a study treatment. However, find ings in 4 patients we re excluded from the final ana lysis because they comm itted protocol violations with respeet to keeping scheduled appoi ntme nts. Therefore, the efficacy analysis was based on the find ings in 33 patients-1 5 in the aqueous group and 18 in the glycer in gro up.
Visit 1. All patients had unilateraI disease.
Dis charge. At visit I, otorrhea was present in 29 of the 33 patie nts (87.9%)-in 12 of the 15 aqueo us patients and in 17 of the 18 glyceri n pat ients (table 2) .
Swelling . Swe lling was present in 3 1 patients (93.9 %); I patien t in each group did not prese nt with swe lling.
Pain. All 33 patients presented with pain.
Redness. Eryt hema was present in 32 patients (97.0%); the lone exce ption was a patient in the aqueo us group.
Pathogens. Cultures were positive in all 33 patients; 7 pat ients had more than one pathogen (table 2) . Of the 40 isolates, 17 were identified as S aureus (42. 5%), 15 as P aeruginosa (37.5%), 4 as Hemophilus spec ies ( 10%), 3 as Proteus species (7.5%), and I as beta-h emolytic streptococci (2.5%). Dua l pathogens were see n in 3 patients in the aqueous group and 4 in the glycerin group. In all 7 cases of multiple iso lates, S aureus was one of the infecting microorganisms; S aureus occ urre d with Hemoph ilus spec ies in 3 pati ent s, with Pro teus species in 3 patients, and with P aeruginosa in I patient. Susceptibility tests showe d that 100% of these pathogens were sensitive to ciprofloxaci n.
Visit 2. All 33 patient s were fully compliant with their treatm ent regi men. At vis it 2, clin ical cure was achieved in 2 of the 15 patient s in the aqueo us gro up (13.3%) and in 4 of the 18 in the glyce rin group (22 .2%) .
Discharge. Improvement was see n in 10 of the 12 aqueous patients (83 .3%) and in all 17 of the glycerin 
Discussion
Topieal antibio tics have been show n to be more effective than systemic antibiotics in resolving otorrhea and in eradica ting bacteria." :" Moreover, co mb ining a topieal and systemic antibio tic is no more effective than using a topi eal antibiotic alone." Ototopical quino lones have been show n patient s-a statistica lly significant differen ce (table 3) . T he 2 pati ents who did not improve showe d no cha nge in discharge status. Swelling. A ll but I patient ex per ienced a reductio n in swe lling (table 4) . Th e exception was a patient in the aqueo us gro up whose ede ma ac tua lly became wo rse (from moderate to inte nse).
Pain. Pain disa ppeared in 13 of the 15 aqueo us patients (86.7 %) and in 16 ofthe 18 (88 .9%) glycerin pat ients . One patient in the aqueous gro up whose pai n persisted required medication wit h intravenous hydrocortisone at visit 2.
Redness. Rates of erythema reso lution were low in both groups. Redness disappeared in only 3 of 14 aq ueo us patients (2 1.4%) and in 5 of 18 glycerin patients (27 .8%).
Side effects. The two treatments were equally we il to lera ted . One patient in eac h gro up repo rted so me pruritus after the treat me nt period ended. No adve rse even t was reported during treatm ent. Visit 3. As ex pected, 100% ofthe pat ien ts in both gro ups had been cured by vis it 3. to be more effective than nonquino lones. " Oto top ica l treatments are very des irable for use in chi ldren, considering the high incidenee Visit 2 (no. pts.) Purulent Mucous None of ea r infections in the pediatric pop ulation.
No ora l antibiotics that are effective against P aeruginosa have been approved for use in children .' The potential for ototoxicity with the use of aminog lycoside otic drops has limi ted their use in chi ldren . Ototoxic ity has been inves tiga ted as a possible adverse effect of oto topica l cipro floxac in thera py in several anima i and clinica l stud ies, but no such ev ide nce has been found.' A preserv ative-free, oto topical 0.2% ciprofloxac in aqueous formula has been developed and supplied in single-dose co ntainers in orde r to.ob viate the need for antim icrobial preservatives. Although this represe nts an ac hieve me nt, the so lution is stiil aqueo us an d it has an aci dic pH , which is an un favorabl e facto r w ith respeet to ciprofloxac in acti vity. In add ition , so me top ieal adverse effects related to the large vo lume of wate r insti lled (0.5 mi) with this formulation have been reported. ' An altemative to otic drops are powders. Topieal antibiotics have been app lied in powder form by insufflation. Ant ibiotic powders de liver a high concentration of antib iotic witho ut contributing to moisturization of the ca nal." However, treatment with powder forms is not effective in patie nts who have a severely ede mato us exte ma l aud itory canal.
As we expected, ou r study showed that bot h trea tme nts wc re very successful in ac hieving clinica l responses at vis it 3, proving aga in that ciprofloxacin is effec tive aga inst the pathogens that are co mmo nly associated wit h ear infections.
Th e differenc e betw een the two groups with respeet to ear drain age was statistica lly significant at a 90% confidenee interval. Thi s differenc e migh t have been the result of the favora ble effect pro vided by the glyceri n vehic le (e.g., the longer contac t tim e between the medication and the target site an d the high degree of hygroscopicity). We obse rved the same pattern w ith respeet to swe lling, pain, and red ness , whic h was less in the glycer in gro up, although not significantly None so. The slower rate of recovery in the aqueous group might have been seco ndary to the presence of wate r, which can cause the ca nal to become ery thematous and maceratcd. On the basis of the clinical and bac ter iolog ic data obtained in this study, we co nelude that the glyce rin form of 0.3% ciprofloxacin appears to be at least as the rudimentary pinn a of our patient precluded any such appositions from existing to a signifi cant degree, which renders this expl anation somewhat unlikely.'
The developing branchial app aratus spans the distance from the lumen of the foregut to the skin . Therefore, we must understand that a small altera tion in its development could lead to an unu sual presentation . As we understand more about this dev elopment, we hope to be in a better position to explain such anomalies. effective as the aqueous form in the treatment ofAEG-and in the case ofdischarge, mor e so. We believe that the glycerin medium minimizes moi sture in the external eal' canal and perhaps even helps dry the mucoid deb ris . Therefore, we believe that the glycerin formulation represent s a more rational design and a good pharma ceutical alternative to the aqueous agent. We intend to conduct furth er studi es to test the glyce rin formulation for other indications.
